Coadministration of Liraglutide With Tacrolimus in Kidney Transplant Recipients: A Case Series
Year: 2013
Type: article
Study design: Case Report
Abstract: G lucocorticoids commonly used inthe posttransplant period havebeen demonstrated to reduce in-sulin sensitivity, impair a-cell function, and more recently, impair b-cell function and the incretin effect (1). Liraglutide is an incretin mimetic approved for the treatment of type 2 diabetes. One major concern about the use of liraglutide after transplantation is that it delays gastric emptying, which could potentially affect absorption of coadministered oral medi-cations, such as tacrolimus, which has a narrow therapeutic index (2). This case series is the first to report on the safety of this drug combination in kidney trans-plant recipients (KTRs). Nonpregnant, adult ($18 years of age), and clinically stable (estimated glo-merular filtration rate [eGFR] $60 mL/min/1.73 m2 and not experiencing allograft rejection or two serum creatinine values.30 % of each other obtained at least 1 week apart within 4 weeks prior to enrollment) KTRs receiving unchanged tacrolimus doses for $4 weeks (goal trough concentration 5–15 ng/mL) were included. Patients with a history of pre-existing diabetes or receiving antihy-perglycemic agents or varying doses of glucocorticoids were excluded. The study was approved by the Henry Ford Hospital and the Wayne State Univer-sity Institutional Review Boards. All par-ticipants provided written informed consent. Measurements were performed be-fore and after self-administration of a 21-day course of liraglutide (0.6 mg for 1 week, 1.2 mg during week 2, and 1.8 mg during week 3). Tacrolimus area under the curve (AUC)0–12h was measured with a previously validated multiple regression– derived limited sampling strategy (3). Fast-ing and postprandial (60 and 120 min after completion of a standardized test meal) blood glucose levels were measured. Body weight and safety and tolerability were captured. Descriptive statistics were performed. Five patients had been exposed to concomitant liraglutide and tacrolimus therapy at our institution (age 55.4 6
Source: Diabetes Care
DOI: 10.2337/dc13-1066
Language: English
Subfield: Transplantation
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W2048952897
